Projected costs associated with school-based screening to inform deployment of Dengvaxia: Vietnam as a case study

Hugo C. Turner, Bridget A. Wills, Motiur Rahman, Hoang Quoc Cuong, Guy E. Thwaites, Maciej F. Boni, Hannah E. Clapham

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: After new analysis, Sanofi Pasteur now recommends their dengue vaccine (Dengvaxia) should only be given to individuals previously infected with dengue and the World Health Organization's recommendations regarding its use are currently being revised. As a result, the potential costs of performing large-scale individual dengue screening and/or dengue serosurveys have become an important consideration for decision making by policymakers in dengue-endemic areas. Methods: We used an ingredients-based approach to estimate the financial costs for conducting both a school-based dengue serosurvey and school-based individual dengue screening within a typical province in Vietnam, using an existing commercial indirect immunoglobulin G enzyme-linked immunosorbent assay kit. This costing is hypothetical and based on estimates regarding the resources that would be required to perform such activities. Results: We estimated that performing a school-based individual screening of 9-year-olds would cost US $9.25 per child tested or US$197,827 in total for a typical province. We also estimated that a school-based serosurvey would cost US$10,074, assuming one class from each of the grades that include 8- to 11-year-olds are sampled at each of the 12 selected schools across the province. Conclusions: The study indicates that using this vaccine safely on a large-scale will incur noteworthy operational costs. It is crucial that these be considered in future cost-effectiveness analyses informing how and where the vaccine is deployed.

Original languageEnglish (US)
Pages (from-to)369-377
Number of pages9
JournalTransactions of the Royal Society of Tropical Medicine and Hygiene
Volume112
Issue number8
DOIs
StatePublished - Jan 1 2018

Fingerprint

Dengue
Vietnam
Costs and Cost Analysis
Dengue Vaccines
Vaccines
Cost-Benefit Analysis
Decision Making
Immunoglobulin G
Enzyme-Linked Immunosorbent Assay

All Science Journal Classification (ASJC) codes

  • Parasitology
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Turner, Hugo C. ; Wills, Bridget A. ; Rahman, Motiur ; Cuong, Hoang Quoc ; Thwaites, Guy E. ; Boni, Maciej F. ; Clapham, Hannah E. / Projected costs associated with school-based screening to inform deployment of Dengvaxia : Vietnam as a case study. In: Transactions of the Royal Society of Tropical Medicine and Hygiene. 2018 ; Vol. 112, No. 8. pp. 369-377.
@article{064ce499ce1c481cabe2c703051981e1,
title = "Projected costs associated with school-based screening to inform deployment of Dengvaxia: Vietnam as a case study",
abstract = "Background: After new analysis, Sanofi Pasteur now recommends their dengue vaccine (Dengvaxia) should only be given to individuals previously infected with dengue and the World Health Organization's recommendations regarding its use are currently being revised. As a result, the potential costs of performing large-scale individual dengue screening and/or dengue serosurveys have become an important consideration for decision making by policymakers in dengue-endemic areas. Methods: We used an ingredients-based approach to estimate the financial costs for conducting both a school-based dengue serosurvey and school-based individual dengue screening within a typical province in Vietnam, using an existing commercial indirect immunoglobulin G enzyme-linked immunosorbent assay kit. This costing is hypothetical and based on estimates regarding the resources that would be required to perform such activities. Results: We estimated that performing a school-based individual screening of 9-year-olds would cost US $9.25 per child tested or US$197,827 in total for a typical province. We also estimated that a school-based serosurvey would cost US$10,074, assuming one class from each of the grades that include 8- to 11-year-olds are sampled at each of the 12 selected schools across the province. Conclusions: The study indicates that using this vaccine safely on a large-scale will incur noteworthy operational costs. It is crucial that these be considered in future cost-effectiveness analyses informing how and where the vaccine is deployed.",
author = "Turner, {Hugo C.} and Wills, {Bridget A.} and Motiur Rahman and Cuong, {Hoang Quoc} and Thwaites, {Guy E.} and Boni, {Maciej F.} and Clapham, {Hannah E.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1093/trstmh/try057",
language = "English (US)",
volume = "112",
pages = "369--377",
journal = "Transactions of the Royal Society of Tropical Medicine and Hygiene",
issn = "0035-9203",
publisher = "Elsevier",
number = "8",

}

Projected costs associated with school-based screening to inform deployment of Dengvaxia : Vietnam as a case study. / Turner, Hugo C.; Wills, Bridget A.; Rahman, Motiur; Cuong, Hoang Quoc; Thwaites, Guy E.; Boni, Maciej F.; Clapham, Hannah E.

In: Transactions of the Royal Society of Tropical Medicine and Hygiene, Vol. 112, No. 8, 01.01.2018, p. 369-377.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Projected costs associated with school-based screening to inform deployment of Dengvaxia

T2 - Vietnam as a case study

AU - Turner, Hugo C.

AU - Wills, Bridget A.

AU - Rahman, Motiur

AU - Cuong, Hoang Quoc

AU - Thwaites, Guy E.

AU - Boni, Maciej F.

AU - Clapham, Hannah E.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: After new analysis, Sanofi Pasteur now recommends their dengue vaccine (Dengvaxia) should only be given to individuals previously infected with dengue and the World Health Organization's recommendations regarding its use are currently being revised. As a result, the potential costs of performing large-scale individual dengue screening and/or dengue serosurveys have become an important consideration for decision making by policymakers in dengue-endemic areas. Methods: We used an ingredients-based approach to estimate the financial costs for conducting both a school-based dengue serosurvey and school-based individual dengue screening within a typical province in Vietnam, using an existing commercial indirect immunoglobulin G enzyme-linked immunosorbent assay kit. This costing is hypothetical and based on estimates regarding the resources that would be required to perform such activities. Results: We estimated that performing a school-based individual screening of 9-year-olds would cost US $9.25 per child tested or US$197,827 in total for a typical province. We also estimated that a school-based serosurvey would cost US$10,074, assuming one class from each of the grades that include 8- to 11-year-olds are sampled at each of the 12 selected schools across the province. Conclusions: The study indicates that using this vaccine safely on a large-scale will incur noteworthy operational costs. It is crucial that these be considered in future cost-effectiveness analyses informing how and where the vaccine is deployed.

AB - Background: After new analysis, Sanofi Pasteur now recommends their dengue vaccine (Dengvaxia) should only be given to individuals previously infected with dengue and the World Health Organization's recommendations regarding its use are currently being revised. As a result, the potential costs of performing large-scale individual dengue screening and/or dengue serosurveys have become an important consideration for decision making by policymakers in dengue-endemic areas. Methods: We used an ingredients-based approach to estimate the financial costs for conducting both a school-based dengue serosurvey and school-based individual dengue screening within a typical province in Vietnam, using an existing commercial indirect immunoglobulin G enzyme-linked immunosorbent assay kit. This costing is hypothetical and based on estimates regarding the resources that would be required to perform such activities. Results: We estimated that performing a school-based individual screening of 9-year-olds would cost US $9.25 per child tested or US$197,827 in total for a typical province. We also estimated that a school-based serosurvey would cost US$10,074, assuming one class from each of the grades that include 8- to 11-year-olds are sampled at each of the 12 selected schools across the province. Conclusions: The study indicates that using this vaccine safely on a large-scale will incur noteworthy operational costs. It is crucial that these be considered in future cost-effectiveness analyses informing how and where the vaccine is deployed.

UR - http://www.scopus.com/inward/record.url?scp=85053344176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053344176&partnerID=8YFLogxK

U2 - 10.1093/trstmh/try057

DO - 10.1093/trstmh/try057

M3 - Article

C2 - 29982700

AN - SCOPUS:85053344176

VL - 112

SP - 369

EP - 377

JO - Transactions of the Royal Society of Tropical Medicine and Hygiene

JF - Transactions of the Royal Society of Tropical Medicine and Hygiene

SN - 0035-9203

IS - 8

ER -